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It is estimated that 30–45% of all adults have hypertension 
with an increasing prevalence with advancing age [1]. Anti-
hypertensive drugs are essential and effective components of 
hypertension management but often limited by non-adher-
ence [2]. Catheter-based renal denervation (RDN) represents 
a device-based hypertension treatment option, which lowers 
blood pressure by targeting renal sympathetic nerve activ-
ity [3, 4]. RDN has proven both, its safety and efficacy in 
recently published, sham-controlled studies [5−7]. These 
studies included mild-moderate hypertensive individuals not 
treated with antihypertensive medication (SPYRAL Hyper-
tension-Off Medication [6], RADIANCE-HTN SOLO—A 
study of the ReCor Medical Paradise System in Clinical 
Hypertension [5]) and patients on 1–3 commonly prescribed 
antihypertensive drugs (SPYRAL Hypertension-On Medica-
tion [7]). In order to put these results into perspective one 
has to keep in mind that the patients enrolled in these trials 
were distinctly different from those investigated in previous 
studies [3, 4], which mainly included severe, resistant hyper-
tensive patients on multiple medications. Hence, the 2013 
European Society of Cardiology (ESC)/European Society 
of Hypertension (ESH) Guidelines for the management of 
hypertension recommended that RDN may be considered 
in patients with uncontrolled resistant hypertension on 3 or 
more different antihypertensive drug classes, one of which 
had to be a diuretic (class of recommendations IIb, level 
of evidence C) [8]. This recommendation was revised in 
the current 2018 ESC/ESH Guidelines [9], where the use 
of device-based therapies (including RDN) for the routine 
treatment of hypertension outside clinical studies is not rec-
ommended, given that the evidence available at the time of 
writing of the guidelines was considered not informative 
enough. However, the 2018 ESC/ESH guidelines called for 
further placebo-controlled trials of device-based therapies. 
In light of the results of the recently published sham-con-
trolled studies, including the first positive pivotal study, soci-
eties may wish to update their recommendations. Against 
this background, the present position paper by the Italian 
Society of Arterial Hypertension aims to clarify some of the 
issues related to patient and center selection for RDN [10].
The manuscript focuses on the importance of adherence 
and persistence as a key component of successful blood 
pressure control but also discusses the high prevalence of 
non-adherence among patients with uncontrolled/difficult 
to control hypertension [10]. The authors discuss the cur-
rent evidence on efficacy and safety of RDN. The first tri-
als—SYMPLICITY Hypertension-1 [3] and Hypertension-2 
[4]—indicated reasonable safety and efficacy of RDN in 
resistant hypertension. However, SYMPLICITY Hyperten-
sion-3 [11] as the first sham-controlled trial failed to meet 
the primary efficacy endpoint. The potential reasons for 
the failure of SYMPLICITY Hypertension-3 [11]—as dis-
cussed in the paper—were, among others, (1) inappropriate 
patient selection, with inclusion of patients with isolated 
systolic hypertension possibly due to advanced end organ 
damage, (2) inconsistent and varying antihypertensive ther-
apy throughout follow-up, (3) lack of adherence measure-
ments and (4) incomplete RDN procedures. This study is 
now contrasted by 3 independently designed randomized, 
sham-controlled studies [5−7]. At the 2020′s annual meet-
ing of the American College of Cardiology the first pivotal 
study on RDN was presented and simultaneously published 
[12]. The trial included 331 patients with a 1:1 randomi-
zation to either radiofrequency RDN or a sham procedure. 
Patients had office systolic blood pressure (SBP) between 
150–180 mmHg and office diastolic blood pressure (DBP) 
of at least 90 mmHg and a mean 24-h SBP in the ambula-
tory blood pressure monitoring (ABPM) of 140–170 mmHg, 
respectively. The primary endpoint was baseline-adjusted 
change in 24-h SBP and the secondary, powered endpoint 
was baseline-adjusted change in office SBP from baseline 
to 3 months. Both efficacy endpoints were met with a treat-
ment difference in SBP according to ABPM of − 3.9 mmHg 
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(Bayesian 95% credible interval − 6.2 to − 1.6) and a differ-
ence of − 6.5 mmHg (− 9.6 to − 3.5) in SBP according to 
office blood pressure measurements.
The expert group of the Italian Society of Hypertension 
provided clear recommendations for patient selection and 
minimum requirements for RDN centers in a coherent flow 
chart. They endorse offering RDN primarily to patients 
with resistant hypertension, despite treatment with renin-
angiotensin-system (RAS)-blockers, diuretics and calcium-
channel-blockers (CCB) at maximally tolerated doses. Also, 
patients with intolerance to one or more of these drugs or 
patients with poor adherence may be considered for RDN. 
RDN procedures should be performed in highly specialized 
hypertension centers, with expertise in hypertension care 
and sufficient experience with renal artery interventions (i.e. 
certified operators, volume of renal procedures > 20/year and 
the equipment to assess ABPM and to screen for causes of 
secondary hypertension).
The flowchart highlights five central approaches to opti-
mize blood pressure-lowering treatment to achieve control, 
before continuing further evaluation for RDN. One of these 
steps is “screening for secondary hypertension”. Of note, the 
prevalence of secondary hypertension among patients with 
uncontrolled hypertension is estimated to be 5–10% [13]. As 
of today, causes for secondary hypertension have not been 
systematically excluded in patients prior enrollment in RDN 
trials and registries. Yet, patients with a known secondary 
hypertension, i.e. primary aldosteronism or Cushing’s syn-
drome, were excluded, thus data on the efficacy of RDN 
in secondary hypertension are lacking. However, one may 
argue that patients with sleep apnea or moderate renal artery 
stenoses may not generally be disqualified for RDN treat-
ment. Future studies are needed to particularly investigate 
this patient cohort at high cardiovascular risk. Whether a 
standardized screening algorithm for all causes of second-
ary hypertension is feasible and useful in clinical practice 
remains to be shown.
Another approach highlighted by the authors is “shared 
decision making”. Shared decision making has become an 
increasingly recognized component of societal guidelines 
[9]. Physicians and health care providers should compre-
hensively discuss the present condition, followed by an 
exchange of knowledge made relevant and understandable to 
the patient with the help of a structured dialog. Shared deci-
sion making is vital in the management of several cardio-
vascular diseases, e.g. aortic valve disease in elderly patients 
or left-main coronary heart disease with low to moderate 
SYNTAX-Score. In the 2019 ESC Guidelines for the diag-
nosis and management of chronic coronary syndromes, for 
instance, it is recommended to include patient’s preference 
not only for selection of potential diagnostic steps in situa-
tions with low pre-test probability, but also for choosing the 
optimal treatment option. Whether shared decision making 
improves hard outcomes in chronically ill patients though, 
is incompletely understood [14]. Shared decision making in 
daily clinical practice however, can be challenging. Patients 
with difficult to control hypertension, who consult Hyperten-
sion Excellence Centers have generally be seen for years by 
several specialists and have likely be treated with various 
antihypertensive drugs in different doses and combinations. 
For these patients, device-based hypertension treatment, 
and in particular RDN, may represent an alternative and 
potentially attractive option. Interestingly, a recent survey 
conducted in Germany revealed that 38.2% of hypertensive 
patients not yet taking antihypertensive medication would 
prefer RDN over life-long medical therapy [15]. The likeli-
hood of preference for RDN was higher in younger patients 
and in men. Eligible patients should be informed about the 
efficacy and safety profile of the technique but also about 
the fact that RDN will likely not replace antihypertensive 
medication in many patients but may reduce blood pressure 
throughout the 24-h cycle [12].
Further, the Italian Society of Hypertension also sug-
gested performing “drug adherence and tolerability assess-
ments”. Drug adherence assessments using toxicological 
analyses have gained significant interest in the scientific 
community but are rather expensive, not widely available, 
laborious measurement with the limitation that dosage 
changes cannot adequately be detected. Moreover, meas-
urement of drug adherence remains often without direct 
therapeutic implications other than patient counselling and 
simplifying antihypertensive drug regimen, all of which 
should be part of contemporary hypertension management 
anyway. However, one may argue that knowledge about drug 
adherence can provide valuable information about patients’ 
willingness to adhere to antihypertensive drugs, which may 
facilitate shared decision making.
In summary, the Italian Society of Hypertension pro-
vided a clinically useful and up to date position paper on 
the role of RDN for the management of the difficult-to-treat 
hypertensive patients. The flowchart is helpful for the selec-
tion of diagnostic and therapeutic approaches. One of the 
welcome shifts under way in medicine is the move towards 
shared decision making, in particular in cardiovascular med-
icine. As patients in clinical practice may differ from those 
enrolled in the most recent RDN trials, we propose a slightly 
revised step-by-step evaluation algorithm depicted in Fig. 1 
highlighting shared decision making. The future of medicine 
lies in sharing medicine, not only within our community of 
learning and practice but more importantly with our patients.
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